← Leaderboards
Erik Knudsen
University Of Cincinnati
$18,973,850
Attributed
$24,292,228
Total exposure
17
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$24,292,228 · 17
By mechanism
R01$22,658,519 · 13
U01$590,988 · 1
T32$446,552 · 1
R21$438,275 · 1
R03$157,894 · 1
Top collaborators
- Agnieszka Witkiewicz20 shared
- Richard G Pestell5 shared
- Chongmin Huan1 shared
Most similar at University Of Cincinnati
Same institution · by research overlap
- Jason Aaron Stewart$1,437,093
- Alvaro Puga$16,644,214
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorResponseMalignant NeoplasmsCell CyclePathway InteractionsTumor Suppressor ProteinsGeneticGenesBaseCessation Of LifeEventComplexResistanceRetinoblastoma Tumor SuppressorMediatingSignal TransductionCell Cycle ProgressionCell Cycle RegulationMalignant Breast NeoplasmPlayTumorigenesisDisease ProgressionCdk4 GeneSpecimen
Grant awards (79)
Delineating the dystopian nature of the cell cycle in cancer$534,959
R01 · FY2025 · CA · contact PI
Impact of RB activation on the pancreatic cancer epigenome and tumor microenvironment$505,216
R01 · FY2025 · CA
Delineating the dystopian nature of the cell cycle in cancer$513,684
R01 · FY2024 · CA · contact PI
Impact of RB activation on the pancreatic cancer epigenome and tumor microenvironment$479,955
R01 · FY2024 · CA
RB tumor suppressor as a therapeutic target in ER-positive breast cancer$408,055
R01 · FY2024 · CA · contact PI
RB tumor suppressor as a therapeutic target in ER-positive breast cancer$316,204
R01 · FY2024 · CA · contact PI
Delineating the dystopian nature of the cell cycle in cancer$538,372
R01 · FY2023 · CA · contact PI
Impact of RB activation on the pancreatic cancer epigenome and tumor microenvironment$505,216
R01 · FY2023 · CA
RB tumor suppressor as a therapeutic target in ER-positive breast cancer$420,941
R01 · FY2023 · CA · contact PI
RB tumor suppressor as a therapeutic target in ER-positive breast cancer$351,338
R01 · FY2023 · CA · contact PI
Delineating the dystopian nature of the cell cycle in cancer$549,360
R01 · FY2022 · CA · contact PI
RB tumor suppressor as a therapeutic target in ER-positive breast cancer$420,941
R01 · FY2022 · CA · contact PI
Replication Licensing in Genome Stability, Cancer and Aging$359,878
R01 · FY2022 · CA · contact PI
RB tumor suppressor as a therapeutic target in ER-positive breast cancer$351,338
R01 · FY2022 · CA · contact PI
RB tumor suppressor as a therapeutic target in ER-positive breast cancer$429,531
R01 · FY2021 · CA · contact PI
Common Genetically Altered Pathways as Targets for Therapy in Pancreatic Cancer$392,993
R01 · FY2021 · CA
Regulation of non-proteolytic ubiquitination in cancer chemoresistance and progression$384,758
R01 · FY2021 · CA · contact PI
Replication Licensing in Genome Stability, Cancer and Aging$367,223
R01 · FY2021 · CA · contact PI
Targeting Cell Cycle Plasticity in Pancreatic Ductal Adenocarcinoma$438,275
R21 · FY2020 · CA
RB tumor suppressor as a therapeutic target in ER-positive breast cancer$429,531
R01 · FY2020 · CA · contact PI
Common Genetically Altered Pathways as Targets for Therapy in Pancreatic Cancer$392,993
R01 · FY2020 · CA
Replication Licensing in Genome Stability, Cancer and Aging$367,223
R01 · FY2020 · CA · contact PI
Role of the RB Tumor Suppression in Liver Tumorigenesis$405,300
R01 · FY2019 · CA · contact PI
Common Genetically Altered Pathways as Targets for Therapy in Pancreatic Cancer$381,202
R01 · FY2019 · CA
Replication Licensing in Genome Stability, Cancer and Aging$356,205
R01 · FY2019 · CA · contact PI
Role of the RB Tumor Suppression in Liver Tumorigenesis$440,813
R01 · FY2018 · CA · contact PI
Common Genetically Altered Pathways as Targets for Therapy in Pancreatic Cancer$392,993
R01 · FY2018 · CA
Pathway Heterogeneity: Etiology and Treatment of TNBC$356,485
R01 · FY2018 · CA · contact PI
Role of the RB tumor suppressor in liver tumorigenesis$387,406
R01 · FY2017 · CA · contact PI
Common genetically altered pathways as targets for therapy in pancreatic cancer$351,131
R01 · FY2017 · CA
Pathway Heterogeneity: Etiology and Treatment of TNBC$164,877
R01 · FY2017 · CA · contact PI
Pathway heterogeneity: etiology and treatment of TNBC$153,636
R01 · FY2017 · CA · contact PI
Role of the RB tumor suppressor in liver tumorigenesis$400,509
R01 · FY2016 · CA · contact PI
Pathway heterogeneity: etiology and treatment of TNBC$318,513
R01 · FY2016 · CA · contact PI
Role of the RB tumor suppressor in liver tumorigenesis$398,137
R01 · FY2015 · CA · contact PI
Pathway heterogeneity: etiology and treatment of TNBC$329,925
R01 · FY2015 · CA · contact PI
Impact of Cyclin D1 Isoforms in Breast Cancer$340,445
R01 · FY2014 · CA
Pathway heterogeneity: etiology and treatment of TNBC$329,925
R01 · FY2014 · CA · contact PI
Action of RB Pathway in Breast Cancer Therapy$310,426
R01 · FY2014 · CA · contact PI
Action of RB Pathway in Breast Cancer Therapy$66,726
R01 · FY2014 · CA · contact PI
Impact of Cyclin D1 Isoforms in Breast Cancer$329,916
R01 · FY2013 · CA
Action of RB Pathway in Breast Cancer Therapy$300,826
R01 · FY2013 · CA · contact PI
Action of RB Pathway in Breast Cancer Therapy$53,182
R01 · FY2013 · CA · contact PI
Impact of Cyclin D1 Isoforms in Breast Cancer$350,974
R01 · FY2012 · CA · contact PI
Action of RB Pathway in Breast Cancer Therapy$311,976
R01 · FY2012 · CA · contact PI
Role of the RB tumor suppressor in liver tumorigenesis$169,149
R01 · FY2012 · CA · contact PI
Role of the RB tumor suppressor in liver tumorigenesis$141,821
R01 · FY2012 · CA · contact PI
Impact of Cyclin D1 Isoforms in Breast Cancer$350,692
R01 · FY2011 · CA · contact PI
Action of RB Pathway in Breast Cancer Therapy$311,875
R01 · FY2011 · CA · contact PI
Role of the RB tumor suppressor in liver tumorigenesis$310,970
R01 · FY2011 · CA · contact PI
Action of RB Pathway in Breast Cancer Therapy$321,003
R01 · FY2010 · CA · contact PI
Role of the RB tumor suppressor in liver tumorigenesis$320,588
R01 · FY2010 · CA · contact PI
Impact of Cyclin D1 Isoforms in Breast Cancer$160,501
R01 · FY2010 · CA · contact PI
Role of the RB tumor suppressor in liver tumorigenesis$320,588
R01 · FY2009 · CA · contact PI
Role of the RB tumor suppressor in liver tumorigenesis$320,761
R01 · FY2008 · CA · contact PI
RB-mediated replication control$240,315
R01 · FY2008 · CA · contact PI
BRG1/BRM: role in RB tumor suppressor signaling$238,697
R01 · FY2008 · CA · contact PI
RB-mediated replication control$193,262
R01 · FY2007 · CA · contact PI
BRG1/BRM: role in RB tumor suppressor signaling$126,046
R01 · FY2007 · CA · contact PI
BRG1/BRM: role in RB tumor suppressor signaling$112,650
R01 · FY2007 · CA · contact PI
Modulation of Aflatoxin B1-induced hepatocarcinogenesis by RB loss$64,074
R03 · FY2007 · ES · contact PI
RB-mediated replication control$43,451
R01 · FY2007 · CA · contact PI
Modulation of Aflatoxin B1-induced hepatocarcinogenesis by RB loss$17,070
R03 · FY2007 · ES · contact PI
Training Program in Cancer Therapeutics$446,552
T32 · FY2006 · CA · contact PI
BRG1/BRM: role in RB tumor suppressor signaling$245,824
R01 · FY2006 · CA · contact PI
RB-mediated replication control$241,810
R01 · FY2006 · CA · contact PI
Modulation: AFB1-induced hepatocarcinogenesis by RB loss$76,750
R03 · FY2006 · ES · contact PI
BRG1/BRM: role in RB tumor suppressor signaling$251,740
R01 · FY2005 · CA
RB-mediated replication control$247,825
R01 · FY2005 · CA
BRG1/BRM: role in RB tumor suppressor signaling$251,740
R01 · FY2004 · CA
RB-mediated replication control$248,012
R01 · FY2004 · CA
RB TUMOR SUPPRESSOR--MECHANISMS OF PROLIFERATION CONTROL$244,987
R01 · FY2003 · CA
RB TUMOR SUPPRESSOR--MECHANISMS OF PROLIFERATION CONTROL$373,957
R01 · FY2002 · CA
Cyclin D1, p16ink4a, and the RB pathway$196,996
U01 · FY2002 · ES
Cyclin D1, p16ink4a, and the RB pathway$196,996
U01 · FY2002 · ES
Cyclin D1, p16ink4a, and the RB pathway$196,996
U01 · FY2002 · ES
RB TUMOR SUPPRESSOR--MECHANISMS OF PROLIFERATION CONTROL$230,923
R01 · FY2001 · CA
RB TUMOR SUPPRESSOR--MECHANISMS OF PROLIFERATION CONTROL$163,897
R01 · FY2001 · CA
RB TUMOR SUPPRESSOR--MECHANISMS OF PROLIFERATION CONTROL$224,198
R01 · FY2000 · CA